lipisorb.com
About company
Clinician Therapeutics has entered into an LOI with BiMolecular Products, for exclusive worldwide rights to pharmaceutical use of Lym-X-Sorb (LXS) as a treatment in cystic fibrosis and malabsorption diseases. The contract represents a very favorable purchase price with downstream payments. Clinician Therapeutics objectives are to reposition the all-natural (GRAS)1 medical nutrition product under NDA Orphan Drug status, compile all clinical data into a “Briefing Document” for FDA presentation, and leverage accelerated regulatory guidance to advance the drug candidate to a late-stage “valuation inflection point” which becomes an attractive acquisition candidate for pharma. They estimate a timeline, in the range 6-9 months. To execute on these objectives, CT has identified alliance partnerships for out-sourcing all or nearly all of business processes with the primary role of the company to monitor and manage the out-sourced activities to limit fixed expenses, and minimize overhead.
